Breast CancerNCT07923643
Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain
A study testing Bupivacaine, Dexamethasone and Magnesium sulfate in people with Breast Cancer and Postoperative Pain, run by Assiut University at 1 site in Egypt.
Trial summary
This prospective, randomized, double-blind, controlled clinical trial will evaluate whether adding magnesium sulfate to dexamethasone-augmented ultrasound-guided pectoral nerve block improves postoperative recovery and analgesia in female patients undergoing elective modified radical mastectomy under general… Read more about this study
- Who is it for?
- Ages 18 to 70 years, women only
- Conditions the study is for
- Breast Cancer, Postoperative Pain, Chronic Postoperative Pain
- What is being tested?
- Bupivacaine, Dexamethasone and Magnesium sulfate
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Nov 2026to Nov 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Female patients aged 18-70 years.
- ASA physical status I-III.
- Scheduled for elective modified radical mastectomy.
- Able to understand the study protocol and complete the QoR-15 questionnaire.
- Provided written informed consent.
Who cannot join
- Patient refusal.
- Allergy to local anesthetics, dexamethasone, magnesium sulfate, or study medications.
- Coagulopathy or anticoagulant therapy.
- Local infection at the injection site.
- Severe hepatic or renal impairment.
- Neuromuscular disorders.
Show all 10Show fewer
- Chronic opioid use or chronic pain syndromes.
- Pregnancy or lactation.
- BMI >35 kg/m².
- Cognitive impairment or inability to communicate effectively.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site
South Egypt Cancer Institute, Assiut University, Egypt
Asyut
Madona South Egypt Cancer Institute, Assiut University, Egypt, 201006265867, madonamisheal90@yahoo.com
About this study
Official title: Effect of Magnesium Sulfate Added to Dexamethasone-Augmented Ultrasound-Guided Pectoral Nerve Block (PECS) Block on Early Quality of Recovery and Chronic Post-Mastectomy Pain Following Modified Radical Mastectomy: A Prospective Randomized Double-Blind Controlled Trial
This prospective, randomized, double-blind, controlled clinical trial will evaluate whether adding magnesium sulfate to dexamethasone-augmented ultrasound-guided pectoral nerve block improves postoperative recovery and analgesia in female patients undergoing elective modified radical mastectomy under general anesthesia. Fifty-four participants will be allocated to two groups. Both groups will receive bupivacaine and dexamethasone for PECS block; the intervention group will additionally receive magnesium sulfate. The primary outcome will be the Quality of Recovery-15 (QoR-15) score at 24 hours after surgery. Secondary outcomes will include postoperative pain scores, opioid consumption, time to first rescue analgesia, postoperative nausea and vomiting, patient satisfaction, block-related complications, intraoperative fentanyl requirements, hemodynamic parameters, and chronic post-mastectomy pain assessed through six months.
- Being tested
- Bupivacaine, Dexamethasone, Magnesium sulfate
- Keywords
- Pectoral Nerve Block (PECS), Magnesium sulfate, dexamethasone, Quality of recovery, chronic pain
- Medical subject headings
- Breast Neoplasms, Pain, Postoperative, Chronic Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BupivacaineDrug
Patients will receive an ultrasound-guided PECS block (10 mL in PECS I and 20 mL in PECS II; total volume 30 mL) using 15ml of 0.5% Bupivacaine 75 mg in both groups
DexamethasoneDrug
Dexamethasone 8 mg will be administered as an adjunct to the PECS block in both groups
Magnesium sulfateDrug
Magnesium sulfate 250 mg will be administered as an adjunct to the PECS block in DM group only
| Study group | Role | What they receive |
|---|---|---|
| Group D | Active comparator | Patients will receive an ultrasound-guided PECS block (10 mL in PECS I and 20 mL in PECS II; total volume 30 mL) using 15ml of 0.5% Bupivacaine 75 mg mixed with 8mg dexamethasone (2ml) and diluted to 30ml with normal saline (13ml) Receives: Drug: Bupivacaine; Drug: Dexamethasone |
| Group DM | Experimental | Patients will receive an ultrasound-guided PECS block (10 mL in PECS I and 20 mL in PECS II; total volume 30 mL) using 15ml of 0.5% Bupivacaine 75mg mixed with 8mg dexamethasone (2ml),250mg magnesium sulfate (2.5ml) and diluted to 30ml with normal saline (10.5ml), Receives: Drug: Bupivacaine; Drug: Dexamethasone; Drug: Magnesium sulfate |
What is being measured
The primary outcome is the main question the study is designed to answer.
Quality of Recovery-15 score at 24 hours after surgery
Total score of the Quality of Recovery-15 questionnaire, ranging from 0 to 150, with higher scores indicating better postoperative recovery.
Measured: 24 hours after surgery
Secondary outcomes (12)
Chronic Post-Mastectomy Pain
Assessing the presence or absence of chronic postoperative pain and its intensity using the Visual Analogue Scale (VAS)minimum value of 0, maximum value of 10, where higher scores mean a worse outcome
Measured: Through 6 months postoperatively
Postoperative Pain Intensity
Evaluating postoperative pain intensity using the Visual Analogue Scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain).
Measured: At arrival to Post- Anesthesia Care Unit (PACU) (0 hour), 2, 4, 6, 12, and 24 hours postoperatively.
Total Postoperative Opioid Consumption
Measuring the total morphine consumption required by the patient as rescue analgesia.
Measured: During the first 24 hours postoperatively
Time to First Request for Rescue Analgesia
Recording the duration from the end of surgery until the patient first requests rescue analgesia (when Visual Analogue Scale (VAS)is 4 or more).
Measured: Within the first 24 hours postoperatively
Patient Satisfaction
Evaluating patient satisfaction with postoperative pain management using a 5-point Likert scale (ranging from very dissatisfied to very satisfied)(minimum value of 1, maximum value of 5, where higher scores mean a better outcome).
Measured: At 24 hours postoperatively.
Block-Related Complications and Adverse Effects
Evaluating the overall incidence of any block-related complications or adverse events (including block failure, local anesthetic systemic toxicity, hematoma, infection, pneumothorax, nerve injury, or magnesium-related side effects), reported as the percentage of affected patients out of the total study population
Measured: Intraoperatively and throughout the 24-hour postoperative period.
Incidence and Severity of Postoperative Nausea
The incidence and severity of postoperative nausea will be assessed during the first 24 hours after surgery. Nausea severity will be measured using an 11-point Numerical Rating Scale (NRS), ranging from 0 (no nausea) to 10 (worst imaginable nausea). Assessments will be performed at 2, 6, 12, and 24 hours postoperatively. The incidence of nausea (NRS > 0) and the severity scores at each assessment time will be recorded.
Measured: During the first 24 hours postoperatively (Assessments will be performed at 2, 6, 12, and 24 hours postoperatively).
Incidence and Frequency of Postoperative Vomiting
The incidence and frequency of postoperative vomiting will be assessed during the first 24 hours after surgery. The occurrence of vomiting and the total number of vomiting episodes will be recorded at 2, 6, 12, and 24 hours postoperatively. The need for rescue antiemetic medication will also be documented.
Measured: During the first 24 hours postoperatively (Assessments will be performed at 2, 6, 12, and 24 hours postoperatively).
Intraoperative Fentanyl Requirements
Measuring the total intraoperative consumption of fentanyl.
Measured: Intraoperatively (during the surgical procedure).
Heart rate
Assessing heart rate values.
Measured: At baseline, after block, every 15 minutes intraoperatively, and at the end of surgery (extubation period).
Mean Arterial Pressure (MAP)
Assessing Mean Arterial Pressure (MAP) values
Measured: At baseline, after block, every 15 minutes intraoperatively, and at the end of surgery (extubation period).
Oxygen Saturation (SpO2)
Assessing peripheral oxygen saturation levels.
Measured: At baseline, after block, every 15 minutes intraoperatively, and at the end of surgery (extubation period).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2026
- Study start1 Nov 2026 (estimated)
- Primary completionNov 2028 (estimated)
- Study completionNov 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (16)Papers the sponsor has linked to this study.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Madona M.NOMAN, Assiut University
- Investigators
- Madona M Noman, MD, Principal investigator, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07923643
- Sponsor's protocol ID
- SECI-IRB 18-2026-850
- Status last verified
- Oct 2026
- First submitted
- 24 Oct 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
He SQ, Liu GY, Yu YH, Wang L, Zhang GY, Peng DS, Bei WX, Chen CL, Lv SH, Zhao ZY, Huang Y, Xiang YQ. Establishing M1 subdivision for de novo nasopharyngeal carcinoma patients receiving immuno-chemotherapy: A multicenter, retrospective cohort study. Oral Oncol. 2024 Dec;159:107074. doi: 10.1016/j.oraloncology.2024.107074. Epub 2024 Oct 10.
PubMed 39393309Sun Y, Jacobson KB, Golovlev V. A multienzyme bioluminescent time-resolved pyrophosphate assay. Anal Biochem. 2007 Aug 15;367(2):201-9. doi: 10.1016/j.ab.2007.04.023. Epub 2007 Apr 25.
PubMed 17540325Norman G. Likert scales, levels of measurement and the "laws" of statistics. Adv Health Sci Educ Theory Pract. 2010 Dec;15(5):625-32. doi: 10.1007/s10459-010-9222-y. Epub 2010 Feb 10.
PubMed 20146096Guo L, Zhao J, She Z, Lu M, Zong Y. Statistical key factors optimization of conditions for hydrogen production from S-TE (solubilization by thermophilic enzyme) waste sludge. Bioresour Technol. 2013 Jun;137:51-6. doi: 10.1016/j.biortech.2013.03.102. Epub 2013 Mar 22.
PubMed 23584408Szalontai G, Besenyei G, Parkanyi L. Homonuclear SQ-DQ correlations in solids: applications of the broadband BaBa scheme to reveal 31P-31P spatial correlations in two-, three-, four-, and five-spin systems. Magn Reson Chem. 2011 Dec;49(12):801-11. doi: 10.1002/mrc.2842. Epub 2011 Nov 18.
PubMed 22102509Dinice J, Mainwaring RD. Pentalogy of Cantrell: a rare congenital abnormality. JAAPA. 2007 Nov;20(11):26-7. doi: 10.1097/01720610-200711000-00016. No abstract available.
PubMed 18035760Skjelbred P, Lokken P. Post-operative pain and inflammatory reaction reduced by injection of a corticosteroid. A controlled trial in bilateral oral surgery. Eur J Clin Pharmacol. 1982;21(5):391-6. doi: 10.1007/BF00542325.
PubMed 7042372Nowhere to hide. Nature. 2009 Jul 16;460(7253):307. doi: 10.1038/460307b. No abstract available.
PubMed 19606096Latham JA, Ji T, Matthews K, Mariano PS, Allen KN, Dunaway-Mariano D. Catalytic Mechanism of the Hotdog-Fold Thioesterase PA1618 Revealed by X-ray Structure Determination of a Substrate-Bound Oxygen Ester Analogue Complex. Chembiochem. 2017 Oct 5;18(19):1935-1943. doi: 10.1002/cbic.201700322. Epub 2017 Aug 30.
PubMed 28741300Houben JM, Giltay EJ, Rius-Ottenheim N, Hageman GJ, Kromhout D. Telomere length and mortality in elderly men: the Zutphen Elderly Study. J Gerontol A Biol Sci Med Sci. 2011 Jan;66(1):38-44. doi: 10.1093/gerona/glq164. Epub 2010 Oct 1.
PubMed 20889650Richebe P, Pouquet O, Jelacic S, Mehta S, Calderon J, Picard W, Rivat C, Cahana A, Janvier G. Target-controlled dosing of remifentanil during cardiac surgery reduces postoperative hyperalgesia. J Cardiothorac Vasc Anesth. 2011 Dec;25(6):917-25. doi: 10.1053/j.jvca.2011.03.185. Epub 2011 Jun 8.
PubMed 21641819McGreevy K, Bottros MM, Raja SN. Preventing Chronic Pain following Acute Pain: Risk Factors, Preventive Strategies, and their Efficacy. Eur J Pain Suppl. 2011 Nov 11;5(2):365-372. doi: 10.1016/j.eujps.2011.08.013.
PubMed 22102847Pawlas N, Broberg K, Skerfving S, Pawlas K. Disturbance of posture in children with very low lead exposure, and modification by VDR FokI genotype. Ann Agric Environ Med. 2014;21(4):739-44. doi: 10.5604/12321966.1129926.
PubMed 25528913Perl T, Carstens E, Hirn A, Quintel M, Vautz W, Nolte J, Junger M. Determination of serum propofol concentrations by breath analysis using ion mobility spectrometry. Br J Anaesth. 2009 Dec;103(6):822-7. doi: 10.1093/bja/aep312. Epub 2009 Nov 3.
PubMed 19887534Riechel C, Alegiani AC, Kopke S, Kasper J, Rosenkranz M, Thomalla G, Heesen C. Subjective and objective knowledge and decisional role preferences in cerebrovascular patients compared to controls. Patient Prefer Adherence. 2016 Aug 2;10:1453-60. doi: 10.2147/PPA.S98342. eCollection 2016.
PubMed 27536077
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Magnesium Sulfate Added to Dexamethasone-Augmented Ultrasound-Guided Pectoral Nerve Block (PECS) Block on Early Quality of Recovery and Chronic Post-Mastectomy Pain Following Modified Radical Mastectomy: A Prospective Randomized Double-Blind Controlled Trial
- ClinicalTrials.gov ID
- NCT07923643
- Acronym / sponsor ID
- SECI-IRB 18-2026-850
- Keywords
- Pectoral Nerve Block (PECS), Magnesium sulfate, dexamethasone, Quality of recovery, chronic pain
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Nov 2026 (estimated)
- Primary completion
- Nov 2028 (estimated)
- Study completion
- Nov 2028 (estimated)
- First posted
- 6 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective, randomized, double-blind, controlled clinical trial will evaluate whether adding magnesium sulfate to dexamethasone-augmented ultrasound-guided pectoral nerve block improves postoperative recovery and analgesia in female patients undergoing elective modified radical mastectomy under general anesthesia. Fifty-four participants will be allocated to two groups. Both groups will receive bupivacaine and dexamethasone for PECS block; the intervention group will additionally receive magnesium sulfate. The primary outcome will be the Quality of Recovery-15 (QoR-15) score at 24 hours after surgery. Secondary outcomes will include postoperative pain scores, opioid consumption, time to first rescue analgesia, postoperative nausea and vomiting, patient satisfaction, block-related complications, intraoperative fentanyl requirements, hemodynamic parameters, and chronic post-mastectomy pain assessed through six months.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group D | Active comparator | Drug: Bupivacaine, Drug: DexamethasonePatients will receive an ultrasound-guided PECS block (10 mL in PECS I and 20 mL in PECS II; total volume 30 mL) using 15ml of 0.5% Bupivacaine 75 mg mixed with 8mg dexamethasone (2ml) and diluted to 30ml with normal saline (13ml) |
| Group DM | Experimental | Drug: Bupivacaine, Drug: Dexamethasone, Drug: Magnesium sulfatePatients will receive an ultrasound-guided PECS block (10 mL in PECS I and 20 mL in PECS II; total volume 30 mL) using 15ml of 0.5% Bupivacaine 75mg mixed with 8mg dexamethasone (2ml),250mg magnesium sulfate (2.5ml) and diluted to 30ml with normal saline (10.5ml), |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Female patients aged 18-70 years.
- ASA physical status I-III.
- Scheduled for elective modified radical mastectomy.
- Able to understand the study protocol and complete the QoR-15 questionnaire.
- Provided written informed consent.
Key exclusion criteria (10 listed)
- Patient refusal.
- Allergy to local anesthetics, dexamethasone, magnesium sulfate, or study medications.
- Coagulopathy or anticoagulant therapy.
- Local infection at the injection site.
- Severe hepatic or renal impairment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BupivacainePatients will receive an ultrasound-guided PECS block (10 mL in PECS I and 20 mL in PECS II; total volume 30 mL) using 15ml of 0.5% Bupivacaine 75 mg in both groups | Drug | Group D, Group DM |
| DexamethasoneDexamethasone 8 mg will be administered as an adjunct to the PECS block in both groups | Drug | Group D, Group DM |
| Magnesium sulfateMagnesium sulfate 250 mg will be administered as an adjunct to the PECS block in DM group only | Drug | Group DM |
Primary outcome
Quality of Recovery-15 score at 24 hours after surgery
Time frame: 24 hours after surgery
Total score of the Quality of Recovery-15 questionnaire, ranging from 0 to 150, with higher scores indicating better postoperative recovery.
12 secondary outcomes
Chronic Post-Mastectomy Pain
Time frame: Through 6 months postoperatively
Postoperative Pain Intensity
Time frame: At arrival to Post- Anesthesia Care Unit (PACU) (0 hour), 2, 4, 6, 12, and 24 hours postoperatively.
Total Postoperative Opioid Consumption
Time frame: During the first 24 hours postoperatively
Time to First Request for Rescue Analgesia
Time frame: Within the first 24 hours postoperatively
Patient Satisfaction
Time frame: At 24 hours postoperatively.
Block-Related Complications and Adverse Effects
Time frame: Intraoperatively and throughout the 24-hour postoperative period.
Incidence and Severity of Postoperative Nausea
Time frame: During the first 24 hours postoperatively (Assessments will be performed at 2, 6, 12, and 24 hours postoperatively).
Incidence and Frequency of Postoperative Vomiting
Time frame: During the first 24 hours postoperatively (Assessments will be performed at 2, 6, 12, and 24 hours postoperatively).
Intraoperative Fentanyl Requirements
Time frame: Intraoperatively (during the surgical procedure).
Heart rate
Time frame: At baseline, after block, every 15 minutes intraoperatively, and at the end of surgery (extubation period).
Mean Arterial Pressure (MAP)
Time frame: At baseline, after block, every 15 minutes intraoperatively, and at the end of surgery (extubation period).
Oxygen Saturation (SpO2)
Time frame: At baseline, after block, every 15 minutes intraoperatively, and at the end of surgery (extubation period).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Background: PubMed 39393309He SQ, Liu GY, Yu YH, Wang L, Zhang GY, Peng DS, Bei WX, Chen CL, Lv SH, Zhao ZY, Huang Y, Xiang YQ. Establishing M1 subdivision for de novo nasopharyngeal carcinoma patients receiving immuno-chemotherapy: A multicenter, retrospective cohort study. Oral Oncol. 2024 Dec;159:107074. doi: 10.1016/j.oraloncology.2024.107074. Epub 2024 Oct 10.
- Background: PubMed 17540325Sun Y, Jacobson KB, Golovlev V. A multienzyme bioluminescent time-resolved pyrophosphate assay. Anal Biochem. 2007 Aug 15;367(2):201-9. doi: 10.1016/j.ab.2007.04.023. Epub 2007 Apr 25.
- Background: PubMed 20146096Norman G. Likert scales, levels of measurement and the "laws" of statistics. Adv Health Sci Educ Theory Pract. 2010 Dec;15(5):625-32. doi: 10.1007/s10459-010-9222-y. Epub 2010 Feb 10.
- Background: PubMed 23584408Guo L, Zhao J, She Z, Lu M, Zong Y. Statistical key factors optimization of conditions for hydrogen production from S-TE (solubilization by thermophilic enzyme) waste sludge. Bioresour Technol. 2013 Jun;137:51-6. doi: 10.1016/j.biortech.2013.03.102. Epub 2013 Mar 22.
- Background: PubMed 22102509Szalontai G, Besenyei G, Parkanyi L. Homonuclear SQ-DQ correlations in solids: applications of the broadband BaBa scheme to reveal 31P-31P spatial correlations in two-, three-, four-, and five-spin systems. Magn Reson Chem. 2011 Dec;49(12):801-11. doi: 10.1002/mrc.2842. Epub 2011 Nov 18.
- Background: PubMed 18035760Dinice J, Mainwaring RD. Pentalogy of Cantrell: a rare congenital abnormality. JAAPA. 2007 Nov;20(11):26-7. doi: 10.1097/01720610-200711000-00016. No abstract available.
- Background: PubMed 7042372Skjelbred P, Lokken P. Post-operative pain and inflammatory reaction reduced by injection of a corticosteroid. A controlled trial in bilateral oral surgery. Eur J Clin Pharmacol. 1982;21(5):391-6. doi: 10.1007/BF00542325.
- Background: PubMed 19606096Nowhere to hide. Nature. 2009 Jul 16;460(7253):307. doi: 10.1038/460307b. No abstract available.
- Background: PubMed 28741300Latham JA, Ji T, Matthews K, Mariano PS, Allen KN, Dunaway-Mariano D. Catalytic Mechanism of the Hotdog-Fold Thioesterase PA1618 Revealed by X-ray Structure Determination of a Substrate-Bound Oxygen Ester Analogue Complex. Chembiochem. 2017 Oct 5;18(19):1935-1943. doi: 10.1002/cbic.201700322. Epub 2017 Aug 30.
- Background: PubMed 20889650Houben JM, Giltay EJ, Rius-Ottenheim N, Hageman GJ, Kromhout D. Telomere length and mortality in elderly men: the Zutphen Elderly Study. J Gerontol A Biol Sci Med Sci. 2011 Jan;66(1):38-44. doi: 10.1093/gerona/glq164. Epub 2010 Oct 1.
- Background: PubMed 21641819Richebe P, Pouquet O, Jelacic S, Mehta S, Calderon J, Picard W, Rivat C, Cahana A, Janvier G. Target-controlled dosing of remifentanil during cardiac surgery reduces postoperative hyperalgesia. J Cardiothorac Vasc Anesth. 2011 Dec;25(6):917-25. doi: 10.1053/j.jvca.2011.03.185. Epub 2011 Jun 8.
- Background: PubMed 22102847McGreevy K, Bottros MM, Raja SN. Preventing Chronic Pain following Acute Pain: Risk Factors, Preventive Strategies, and their Efficacy. Eur J Pain Suppl. 2011 Nov 11;5(2):365-372. doi: 10.1016/j.eujps.2011.08.013.
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Madona M Noman, MD principal investigator
Assiut University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Bupivacaine, Dexamethasone and Magnesium sulfate in people with Breast Cancer and Postoperative Pain, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Madona M Noman, MD (201006265867, madonamisheal90@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quality of Recovery-15 score at 24 hours after surgery (time frame: 24 hours after surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07923643, which also lists 16 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.